Valuation: Cogent Biosciences, Inc.

Market Cap 6.58B 5.76B 5.33B 4.92B 9.25B 633B 9.44B 63.57B 24.9B 309B 24.72B 24.17B 1,068B P/E 2026 *
-16.9x
P/E 2027 * -46.6x
Enterprise Value 6.53B 5.72B 5.28B 4.87B 9.18B 628B 9.36B 63.04B 24.69B 307B 24.51B 23.97B 1,059B EV / Sales 2026 *
690x
EV / Sales 2027 * 18.9x
Free-Float
99.5%
Yield 2026 *
-
Yield 2027 * -
1 day+2.80%
1 week-3.75%
Current month-0.49%
1 month+16.34%
3 months+5.54%
6 months+1.91%
Current year+8.42%
1 week 37.04
Extreme 37.04
40.89
1 month 32.42
Extreme 32.42
40.89
Current year 30.87
Extreme 30.87
41.35
1 year 10.38
Extreme 10.38
43.73
3 years 3.67
Extreme 3.67
43.73
5 years 3.67
Extreme 3.67
43.73
10 years 3.67
Extreme 3.67
43.73
Manager TitleAgeSince
Chief Executive Officer 50 2020-10-22
Director of Finance/CFO 45 2018-05-31
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 68 2018-01-31
Director/Board Member 74 2019-07-25
Director/Board Member 59 2019-07-25
Date Insider Type Main position Quantity % Market Cap.
06-30Free

Director

627 0.0004%
06-08Free

Director

17,901 0.0105%
06-08Free

Director

17,901 0.0105%
Change 5-day change 1-year change 3-year change Capi.($)
+2.80%-3.75%+247.25%+207.34% 6.4B
+6.05%+3.69%+65.28%+89.94% 53.54B
+0.21%-6.28%+56.18%+127.90% 54.18B
+0.89%-2.42%+8.07%+434.51% 23.66B
+0.37%-4.13%-18.56%-16.48% 22.78B
+2.36%+3.86%+42.80%-6.60% 19.54B
-2.29%-1.92%+35.57%-29.14% 17.82B
-4.00%-10.96%+181.91%+328.17% 16.01B
-1.15%-3.07%+45.33%+654.85% 15.37B
-0.48%-2.30%+22.36%+187.62% 14.09B
Average +0.48%-1.82%+68.62%+197.81% 24.34B
Weighted average by Cap. +1.23%-0.58%+54.58%+165.54%

Financials

2026 *2027 *
Net sales 9.46M 8.29M 7.66M 7.07M 13.3M 910M 13.57M 91.38M 35.79M 445M 35.54M 34.75M 1.53B 345M 302M 279M 258M 485M 33.22B 495M 3.34B 1.31B 16.23B 1.3B 1.27B 56.02B
Net income -392M -343M -317M -292M -551M -37.67B -562M -3.78B -1.48B -18.41B -1.47B -1.44B -63.52B -134M -117M -109M -100M -188M -12.89B -192M -1.29B -507M -6.3B -503M -492M -21.75B
Net Debt -55.22M -48.35M -44.69M -41.24M -77.64M -5.31B -79.19M -533M -209M -2.6B -207M -203M -8.96B -63.88M -55.93M -51.7M -47.7M -89.81M -6.14B -91.61M -617M -242M -3B -240M -235M -10.36B
Logo Cogent Biosciences, Inc.
Cogent Biosciences, Inc. is a clinical-stage biotechnology company. It is focused on developing precision therapies for genetically defined diseases. Its approach is to design rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its advanced program is bezuclastinib, also known as CGT9486, a highly selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis (SM), a serious and rare disease caused by unchecked proliferation of mast cells. The Company has on-going Phase I studies of its CNS-penetrant, selective mutant ErbB2 inhibitor and its potential best-in-class, wild-type-sparing, PI3Ka inhibitor. In addition, the Company’s research team is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases targeting mutations in KRAS and JAK2.
Employees
258
Date Price Change Volume
26-07-14 US$38.51 +2.80% 2,076,036
26-07-13 US$37.46 -3.63% 1,610,211
26-07-10 US$38.87 -4.05% 2,051,963
26-07-09 US$40.51 +1.35% 3,868,274
26-07-08 US$39.97 -0.10% 3,643,211
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
37.46USD
Average target price
54.25USD
Spread / Average Target
+44.82%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. COGT Stock